Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EXAS Exact Sciences	$44.99 +0.2%	$50.59	$38.81 ▼ $72.83	$8.50B	0.93	3.69 million shs	4.09 million shs
GHDX Genomic Health	$63.44	$64.79	$50.77 ▼ $90.18	$2.38B	0.9	1.05 million shs	N/A
HALO Halozyme Therapeutics	$65.54 +0.6%	$56.80	$42.01 ▼ $70.50	$8.03B	1.17	1.79 million shs	1.60 million shs
MDGL Madrigal Pharmaceuticals	$371.37 -0.6%	$308.52	$200.63 ▼ $377.46	$8.29B	-1.02	430,741 shs	322,224 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EXAS Exact Sciences	+0.18%	+4.24%	-15.10%	-20.26%	-20.17%
GHDX Genomic Health	0.00%	0.00%	0.00%	0.00%	0.00%
HALO Halozyme Therapeutics	+0.63%	+5.54%	+15.80%	+25.99%	+14.16%
MDGL Madrigal Pharmaceuticals	-0.56%	+8.50%	+19.36%	+27.64%	+52.65%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EXAS Exact Sciences	4.8518 of 5 stars	4.5	5.0	0.0	4.7	2.4	2.5	0.6
GHDX Genomic Health	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	4.5816 of 5 stars	2.1	1.0	0.0	4.4	2.8	2.5	4.4
MDGL Madrigal Pharmaceuticals	3.681 of 5 stars	2.4	0.0	0.0	4.6	2.5	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EXAS Exact Sciences	2.92	Moderate Buy	$67.43	49.87% Upside
GHDX Genomic Health	0.00	N/A	N/A	N/A
HALO Halozyme Therapeutics	2.18	Hold	$66.56	1.55% Upside
MDGL Madrigal Pharmaceuticals	2.88	Moderate Buy	$439.71	18.40% Upside

Current Analyst Ratings Breakdown

Latest GHDX, EXAS, HALO, and MDGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	EXAS Exact Sciences	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$65.00 ➝ $60.00
8/12/2025	MDGL Madrigal Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$458.00 ➝ $523.00
8/11/2025	EXAS Exact Sciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$70.00 ➝ $60.00
8/8/2025	EXAS Exact Sciences	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$68.00 ➝ $64.00
8/7/2025	EXAS Exact Sciences	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/7/2025	EXAS Exact Sciences	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$61.00 ➝ $53.00
8/7/2025	EXAS Exact Sciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$54.00 ➝ $46.00
8/7/2025	EXAS Exact Sciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$65.00 ➝ $55.00
8/7/2025	HALO Halozyme Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$60.00 ➝ $63.00
8/6/2025	HALO Halozyme Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$78.00 ➝ $91.00
8/6/2025	HALO Halozyme Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$72.00 ➝ $75.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EXAS Exact Sciences	$2.76B	3.09	$5.64 per share	7.97	$13.04 per share	3.45
GHDX Genomic Health	$394.11M	6.05	$1.45 per share	43.76	$7.48 per share	8.48
HALO Halozyme Therapeutics	$1.02B	7.95	$4.68 per share	14.00	$2.70 per share	24.27
MDGL Madrigal Pharmaceuticals	$180.13M	45.77	N/A	N/A	$31.35 per share	11.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EXAS Exact Sciences	-$1.03B	-$5.43	N/A	89.98	4.59	-34.19%	-1.75%	-0.76%	N/A
GHDX Genomic Health	$25.68M	$1.05	60.42	36.88	N/A	12.81%	19.62%	14.89%	N/A
HALO Halozyme Therapeutics	$444.09M	$4.37	15.00	10.54	0.36	47.28%	150.85%	29.19%	10/30/2025 (Estimated)
MDGL Madrigal Pharmaceuticals	-$465.89M	-$12.85	N/A	N/A	N/A	-54.68%	-38.38%	-27.32%	10/30/2025 (Estimated)

Latest GHDX, EXAS, HALO, and MDGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	EXAS Exact Sciences	-$0.02	$0.22	+$0.24	-$0.01	$774.43 million	$811.09 million
8/5/2025	Q2 2025	HALO Halozyme Therapeutics	$1.23	$1.54	+$0.31	$1.33	$282.66 million	$325.72 million
8/5/2025	Q2 2025	MDGL Madrigal Pharmaceuticals	-$3.48	-$1.90	+$1.58	-$1.90	$158.94 million	$212.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EXAS Exact Sciences	N/A	N/A	N/A	N/A	N/A
GHDX Genomic Health	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EXAS Exact Sciences	0.94	2.89	2.56
GHDX Genomic Health	0.15	5.96	5.96
HALO Halozyme Therapeutics	4.54	8.36	7.01
MDGL Madrigal Pharmaceuticals	0.17	5.11	4.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EXAS Exact Sciences	88.82%
GHDX Genomic Health	93.87%
HALO Halozyme Therapeutics	97.79%
MDGL Madrigal Pharmaceuticals	98.50%

Insider Ownership

Company	Insider Ownership
EXAS Exact Sciences	1.20%
GHDX Genomic Health	31.30%
HALO Halozyme Therapeutics	2.40%
MDGL Madrigal Pharmaceuticals	21.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EXAS Exact Sciences	7,000	189.32 million	187.05 million	Optionable
GHDX Genomic Health	829	37.59 million	N/A	Optionable
HALO Halozyme Therapeutics	390	123.22 million	120.26 million	Optionable
MDGL Madrigal Pharmaceuticals	90	22.20 million	17.43 million	Optionable

GHDX, EXAS, HALO, and MDGL Headlines

Recent News About These Companies

Madrigal Pharmaceuticals (MDGL) Gets a Buy from Jefferies

3 hours ago | theglobeandmail.com

Akero Therapeutics: Why I'm Reversing My Contrarian Buy Rating To A Contrarian Sell Rating

3 hours ago | seekingalpha.com

Rebecca Taub Sells 3,200 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock

August 14 at 7:33 AM | insidertrades.com

UBS Group Issues Positive Forecast for Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price

August 13 at 10:25 AM | marketbeat.com

Informed Momentum Co LLC Invests $4.82 Million in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

August 13 at 6:27 AM | marketbeat.com

Chicago Partners Investment Group LLC Takes $277,000 Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

August 13 at 3:44 AM | marketbeat.com

1,003 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Acquired by Blair William & Co. IL

August 13 at 3:22 AM | marketbeat.com

Madrigal Pharmaceuticals (NASDAQ:MDGL) Earns "Buy" Rating from UBS Group

August 13 at 2:54 AM | americanbankingnews.com

Madrigal Pharmaceuticals price target raised to $523 from $458 at UBS

August 12 at 12:49 AM | msn.com

Madrigal Pharmaceuticals to Present at Canaccord Genuity Growth Conference

August 12 at 12:49 AM | msn.com

Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

August 11, 2025 | finance.yahoo.com

Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

August 11, 2025 | globenewswire.com

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock Position Decreased by Connor Clark & Lunn Investment Management Ltd.

August 11, 2025 | marketbeat.com

Party Time: Brokers Just Made Major Increases To Their Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Earnings Forecasts

August 10, 2025 | finance.yahoo.com

XTX Topco Ltd Purchases New Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

August 10, 2025 | marketbeat.com

LPL Financial LLC Buys 25,602 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

August 10, 2025 | marketbeat.com

Cantor Fitzgerald Issues Positive Outlook for MDGL Earnings

August 10, 2025 | americanbankingnews.com

Leerink Partnrs Issues Pessimistic Outlook for MDGL Earnings

August 10, 2025 | americanbankingnews.com

FY2025 EPS Estimates for MDGL Raised by Cantor Fitzgerald

August 9, 2025 | marketbeat.com

Leerink Partnrs Issues Negative Forecast for MDGL Earnings

August 9, 2025 | marketbeat.com

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Sold by Tao Capital Management LP

August 9, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GHDX, EXAS, HALO, and MDGL Company Descriptions

Exact Sciences NASDAQ:EXAS

$44.99 +0.08 (+0.18%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$45.30 +0.31 (+0.69%)

As of 04:31 AM Eastern

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Genomic Health NASDAQ:GHDX

Genomic Health, Inc., a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions. It offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit. The company also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy; Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk prostate cancer, as well as to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score; and Oncotype DX AR-V7 nucleus detect tests for men with metastatic castration-resistant prostate cancer. In addition, it develops Oncoytpe DXi IVD breast recurrence score test; and Oncotype DX GPS test. The company offers its products through a network of distributors. Genomic Health, Inc. has license and development agreement with Biocartis N.V. to develop and commercialize an in vitro diagnostic of the Oncotype DX breast cancer test; collaboration agreement with Epic Sciences, Inc. to commercializeAR-V7 Nucleus Detect test; and license and development agreement with Cleveland Diagnostics, Inc. to develop and commercialize new prostate cancer tests. The company was founded in 2000 and is based in Redwood City, California.

Halozyme Therapeutics NASDAQ:HALO

$65.54 +0.41 (+0.63%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$65.70 +0.16 (+0.25%)

As of 08/14/2025 07:59 PM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Madrigal Pharmaceuticals NASDAQ:MDGL

$371.37 -2.09 (-0.56%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$371.00 -0.37 (-0.10%)

As of 08/14/2025 07:38 PM Eastern

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time